{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:33:41Z","timestamp":1781649221686,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"DOI":"10.7759\/cureus.107540","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:41:58Z","timestamp":1776879718000},"source":"Crossref","is-referenced-by-count":1,"title":["Dual-Site Inflammation During Adalimumab Therapy: Birdshot Chorioretinopathy Complicated by Paradoxical Psoriasis"],"prefix":"10.7759","author":[{"given":"Diana","family":"Naumkinaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Virpsaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Radaviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadas","family":"Raudonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrius","family":"Cimbalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164772","article-title":"Birdshot chorioretinopathy: a review","volume":"11","author":"Bousquet E","year":"2022","unstructured":"Bousquet E, Duraffour P, Debillon L, Somisetty S, Monnet D, Br\u00e9zin AP. Birdshot chorioretinopathy: a review. J Clin Med. 2022, 11:4772. 10.3390\/jcm11164772","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.03.059","article-title":"Classification criteria for birdshot chorioretinitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for birdshot chorioretinitis. Am J Ophthalmol. 2021, 228:65-71. 10.1016\/j.ajo.2021.03.059","journal-title":"Am J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese CA","year":"2024","unstructured":"Maronese CA, Valenti M, Moltrasio C, et al.. Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options. J Invest Dermatol. 2024, 144:2364-76. 10.1016\/j.jid.2024.05.015","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164808","article-title":"HLA-A29 negative birdshot-like chorioretinopathy associated with Vitiligo - case report","volume":"13","author":"Krzemi\u0144ska J","year":"2024","unstructured":"Krzemi\u0144ska J, Kurek A, \u017bebrowska A, Waszczykowska A. HLA-A29 negative birdshot-like chorioretinopathy associated with Vitiligo - case report. J Clin Med. 2024, 13:4808. 10.3390\/jcm13164808","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02425-y","article-title":"The incidence, presenting clinical findings and treatment patterns of birdshot retinochoroiditis in a high-prevalence region: findings from Northern Ireland, England and Wales","volume":"37","author":"Khalil R","year":"2023","unstructured":"Khalil R, Petrushkin H, Rees A, Westcott M. The incidence, presenting clinical findings and treatment patterns of birdshot retinochoroiditis in a high-prevalence region: findings from Northern Ireland, England and Wales. Eye (Lond). 2023, 37:2817-25. 10.1038\/s41433-023-02425-y","journal-title":"Eye (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0429-8","article-title":"Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment","volume":"11","author":"Minos E","year":"2016","unstructured":"Minos E, Barry RJ, Southworth S, et al.. Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis. 2016, 11:61. 10.1186\/s13023-016-0429-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.08.025","article-title":"Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference","volume":"141","author":"Levinson RD","year":"2006","unstructured":"Levinson RD, Brezin A, Rothova A, Accorinti M, Holland GN. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006, 141:185-7. 10.1016\/j.ajo.2005.08.025","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309764","article-title":"Why birdshot retinochoroiditis should rather be called 'HLA-A29 uveitis'?","volume":"101","author":"Herbort CP Jr","year":"2017","unstructured":"Herbort CP Jr, Pav\u00e9sio C, LeHoang P, et al.. Why birdshot retinochoroiditis should rather be called 'HLA-A29 uveitis'?. Br J Ophthalmol. 2017, 101:851-5. 10.1136\/bjophthalmol-2016-309764","journal-title":"Br J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.009","article-title":"High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis","volume":"271","author":"Pichi F","year":"2025","unstructured":"Pichi F, AlAli SH, Jimenez YP, Neri P. High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis. Am J Ophthalmol. 2025, 271:381-8. 10.1016\/j.ajo.2024.12.009","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165288","article-title":"Long-term outcomes of birdshot chorioretinopathy treated with corticosteroids: a case reports","volume":"12","author":"Ferracci D","year":"2023","unstructured":"Ferracci D, Mathis T, Gavoille A, et al.. Long-term outcomes of birdshot chorioretinopathy treated with corticosteroids: a case reports. J Clin Med. 2023, 12:5288. 10.3390\/jcm12165288","journal-title":"J Clin Med"},{"key":"ref11","article-title":"Corticosteroid Adverse Effects","author":"Yasir M","year":"2026","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-023-00349-y","article-title":"Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies","volume":"10","author":"Zhang X","year":"2023","unstructured":"Zhang X, Lim CZ, Chhablani J, Wong YM. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023, 10:33. 10.1186\/s40662-023-00349-y","journal-title":"Eye Vis (Lond)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1402396","article-title":"The application of dexamethasone implants in uveitis treatment","volume":"11","author":"Zhang T","year":"2024","unstructured":"Zhang T, Liu Z, Li N. The application of dexamethasone implants in uveitis treatment. Front Med (Lausanne). 2024, 11:1402396. 10.3389\/fmed.2024.1402396","journal-title":"Front Med (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-019-0189-4","article-title":"Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence","volume":"10","author":"Saincher SS","year":"2020","unstructured":"Saincher SS, Gottlieb C. Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect. 2020, 10:1. 10.1186\/s12348-019-0189-4","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo A","year":"2020","unstructured":"Bucalo A, Rega F, Zangrilli A, et al.. Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020, 21:10.3390\/ijms21217873","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. The yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas A","year":"2018","unstructured":"Mylonas A, Conrad C. Psoriasis: classical vs. paradoxical. The yin-yang of TNF and type I interferon. Front Immunol. 2018, 9:2746. 10.3389\/fimmu.2018.02746","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42791","article-title":"Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment","volume":"15","author":"Chokshi A","year":"2023","unstructured":"Chokshi A, Demory Beckler M, Laloo A, Kesselman MM. Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment. Cureus. 2023, 15:e42791. 10.7759\/cureus.42791","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/rq4k3u","article-title":"Anti-TNF-\u03b1 induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review","volume":"42","author":"Sagonas I","year":"2024","unstructured":"Sagonas I, Iliopoulos G, Baraliakos X, Daoussis D. Anti-TNF-\u03b1 induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review. Clin Exp Rheumatol. 2024, 42:178-84. 10.55563\/clinexprheumatol\/rq4k3u","journal-title":"Clin Exp Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.11.062","article-title":"Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: a series of 170 clinically- and patch test-confirmed cases","volume":"92","author":"Wu PA","year":"2025","unstructured":"Wu PA, Wu J, Liu R, et al.. Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: a series of 170 clinically- and patch test-confirmed cases. J Am Acad Dermatol. 2025, 92:853-60. 10.1016\/j.jaad.2024.11.062","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1184289","article-title":"Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches","volume":"10","author":"Tramontana M","year":"2023","unstructured":"Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. Front Med (Lausanne). 2023, 10:1184289. 10.3389\/fmed.2023.1184289","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100211","article-title":"Paradoxical psoriasis: the flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?","volume":"7","author":"Lu J","year":"2023","unstructured":"Lu J, Lu Y. Paradoxical psoriasis: the flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?. J Transl Autoimmun. 2023, 7:100211. 10.1016\/j.jtauto.2023.100211","journal-title":"J Transl Autoimmun"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/2475530318810851","article-title":"TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management","volume":"4","author":"Li SJ","year":"2019","unstructured":"Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019, 4:70-80. 10.1177\/2475530318810851","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot \u00c9","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016, 2:e000239. 10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna F","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020, 10:11. 10.1186\/s12348-020-00202-6","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad C","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al.. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018, 9:25. 10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137018","article-title":"Paradoxical psoriasis in patients receiving therapy with tumor necrosis factor inhibitors: potential pathogenic mechanisms and the role of genetic factors","volume":"25","author":"Costin D","year":"2024","unstructured":"Costin D, Burlui AM, Cardoneanu A, et al.. Paradoxical psoriasis in patients receiving therapy with tumor necrosis factor inhibitors: potential pathogenic mechanisms and the role of genetic factors. Int J Mol Sci. 2024, 25:7018. 10.3390\/ijms25137018","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie M","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005, 7:R666-76. 10.1186\/ar1724","journal-title":"Arthritis Res Ther"},{"key":"ref28","article-title":"Is TNF-\u03b1 inhibitor-induced psoriasiform dermatitis always psoriasiform?","volume":"19","author":"Wei C","year":"2020","unstructured":"Wei C, Murphy EC, Zahn J, Friedman AJ. Is TNF-\u03b1 inhibitor-induced psoriasiform dermatitis always psoriasiform?. J Drugs Dermatol. 2020, 19:1009-10.","journal-title":"J Drugs Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-024-00443-9","article-title":"Long-term effects of tocilizumab on retinal and choroidal inflammation in birdshot uveitis","volume":"14","author":"Zur Bonsen LS","year":"2024","unstructured":"Zur Bonsen LS, Schulze D, K\u00fcnzel SE, R\u00fcbsam A, Pleyer U, Pohlmann D. Long-term effects of tocilizumab on retinal and choroidal inflammation in birdshot uveitis. J Ophthalmic Inflamm Infect. 2024, 14:61. 10.1186\/s12348-024-00443-9","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.05.014","article-title":"Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis","volume":"132","author":"Leclercq M","year":"2025","unstructured":"Leclercq M, Jacquot R, Charbonnier C, et al.. Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis. Ophthalmology. 2025, 132:1134-41. 10.1016\/j.ophtha.2025.05.014","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.017","article-title":"Disease heterogeneity and molecular classification of inflammatory palmoplantar diseases","volume":"154","author":"van Straalen KR","year":"2024","unstructured":"van Straalen KR, Kirma J, Yee CM, et al.. Disease heterogeneity and molecular classification of inflammatory palmoplantar diseases. J Allergy Clin Immunol. 2024, 154:1204-1215.e9. 10.1016\/j.jaci.2024.07.017","journal-title":"J Allergy Clin Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02376","article-title":"Neutrophils in psoriasis","volume":"10","author":"Chiang CC","year":"2019","unstructured":"Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in psoriasis. Front Immunol. 2019, 10:2376. 10.3389\/fimmu.2019.02376","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103273","article-title":"Emerging therapies for palmoplantar pustulosis with a focus on IL-23 inhibitors","volume":"14","author":"Nam KH","year":"2025","unstructured":"Nam KH, Kim YS. Emerging therapies for palmoplantar pustulosis with a focus on IL-23 inhibitors. J Clin Med. 2025, 14:3273. 10.3390\/jcm14103273","journal-title":"J Clin Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640473","article-title":"Pathogenesis of non-infectious uveitis elucidated by recent genetic findings","volume":"12","author":"Takeuchi M","year":"2021","unstructured":"Takeuchi M, Mizuki N, Ohno S. Pathogenesis of non-infectious uveitis elucidated by recent genetic findings. Front Immunol. 2021, 12:640473. 10.3389\/fimmu.2021.640473","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09038-1","article-title":"Th17 response in uveitis: a double-edged sword in ocular inflammation and immune regulation","volume":"68","author":"Zong Y","year":"2025","unstructured":"Zong Y, Tong X, Chong WP. Th17 response in uveitis: a double-edged sword in ocular inflammation and immune regulation. Clin Rev Allergy Immunol. 2025, 68:26. 10.1007\/s12016-025-09038-1","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick AD","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, et al.. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018, 125:757-73. 10.1016\/j.ophtha.2017.11.017","journal-title":"Ophthalmology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick AD","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013, 120:777-87. 10.1016\/j.ophtha.2012.09.040","journal-title":"Ophthalmology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple KL","year":"2018","unstructured":"Pepple KL, Lin P. Targeting interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018, 125:1977-83. 10.1016\/j.ophtha.2018.05.014","journal-title":"Ophthalmology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast A","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al.. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020, 34:2461-98. 10.1111\/jdv.16915","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer LM","year":"2019","unstructured":"Sawyer LM, Malottki K, Sabry-Grant C, et al.. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One. 2019, 14:e0220868. 10.1371\/journal.pone.0220868","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1569245","article-title":"Poor control of sarcoidosis-related panuveitis with an antibody to IL-23","volume":"28","author":"Thomas AS","year":"2020","unstructured":"Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020, 28:491-3. 10.1080\/09273948.2019.1569245","journal-title":"Ocul Immunol Inflamm"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318781760","article-title":"Ustekinumab in psoriatic arthritis and related phenotypes","volume":"9","author":"Dobbin-Sears I","year":"2018","unstructured":"Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis. 2018, 9:191-8. 10.1177\/2040622318781760","journal-title":"Ther Adv Chronic Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199616","article-title":"The phenomenon of anti-drug antibodies in psoriasis: mechanisms, clinical impact, and therapeutic strategies","volume":"26","author":"Mennella A","year":"2025","unstructured":"Mennella A, Frasca L. The phenomenon of anti-drug antibodies in psoriasis: mechanisms, clinical impact, and therapeutic strategies. Int J Mol Sci. 2025, 26:9616. 10.3390\/ijms26199616","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.34206","article-title":"Ustekinumab demonstrates lower uveitis risk in moderate to severe psoriasis patients compared with tumor necrosis factor-\u03b1 inhibitors","volume":"104","author":"Bang CH","year":"2024","unstructured":"Bang CH, Oh HJ, Kim YH, Jung JH, Lee JH, Park YM, Han JH. Ustekinumab demonstrates lower uveitis risk in moderate to severe psoriasis patients compared with tumor necrosis factor-\u03b1 inhibitors. Acta Derm Venereol. 2024, 104:adv34206. 10.2340\/actadv.v104.34206","journal-title":"Acta Derm Venereol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2025.24078","article-title":"Uveitis in psoriatic arthritis: a comprehensive review","volume":"12","author":"Deligeorgakis D","year":"2025","unstructured":"Deligeorgakis D, Skouvaklidou E, Skepastianos V, Tsafis K, Kougkas N. Uveitis in psoriatic arthritis: a comprehensive review. Eur J Rheumatol. 2025, 12:1-7. 10.5152\/eurjrheum.2025.24078","journal-title":"Eur J Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1412930","article-title":"Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond","volume":"4","author":"Chauhan K","year":"2024","unstructured":"Chauhan K, Tyagi M. Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. Front Ophthalmol (Lausanne). 2024, 4:1412930. 10.3389\/fopht.2024.1412930","journal-title":"Front Ophthalmol (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/483931-dual-site-inflammation-during-adalimumab-therapy-birdshot-chorioretinopathy-complicated-by-paradoxical-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:41:59Z","timestamp":1776879719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/483931-dual-site-inflammation-during-adalimumab-therapy-birdshot-chorioretinopathy-complicated-by-paradoxical-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.107540","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}